This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Curium, PeptiDream complete prostate...
Tech clinical trial completion

Curium, PeptiDream complete prostate cancer trial

Analysis based on 6 articles · First reported Jun 11, 2026 · Last updated Jun 11, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The completion of patient dosing in the Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan is a positive development for the pharmaceutical and biotechnology sectors. It signals progress towards a new diagnostic tool for prostate cancer, potentially benefiting companies like PeptiDream and Curium Pharma through future regulatory approvals and market expansion in Japan.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Curium Pharma, PeptiDream, and PDRadiopharma announced the completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan. This PET radiopharmaceutical targets prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis. Data analysis is now underway to support future regulatory submission in Japan. The trial evaluates the sensitivity, specificity, and safety of 64Cu-PSMA-I&T in Japanese patients with newly diagnosed unfavorable intermediate, high, or very high-risk prostate cancer. This collaboration also involves advancing a therapeutic counterpart, 177Lu-PSMA-I&T, for metastatic castration-resistant prostate cancer (mCRPC). The partnership leverages Curium Pharma's global development expertise and PDRadiopharma's local knowledge for market entry in Japan, addressing the significant prevalence of prostate cancer in the country.

Entities Involved
priv
Curium Pharma
Curium Pharma, a global radiopharmaceutical company, is a key partner in the clinical development of 64Cu-PSMA-I&T and 177Lu-PSMA-I&T, leading global development and supporting technology transfer to Japan. The completion of patient dosing in the Phase 2 trial in Japan is a significant milestone for its mission to expand access to radiopharmaceuticals in Asia.
Importance 100.0 Sentiment 70.0
stock
PeptiDream
PeptiDream, through its subsidiary PDRadiopharma, is a crucial partner in the clinical trial, leading regulatory filing, manufacturing, commercialization, and distribution activities in Japan. The completion of patient dosing marks an important milestone in its growing radiopharmaceutical pipeline and theranostics strategy.
Importance 100.0 Sentiment 70.0
priv
PDRadiopharma
PDRadiopharma, a wholly-owned subsidiary of PeptiDream, is leading the regulatory filing, manufacturing, commercialization, and distribution of 64Cu-PSMA-I&T and 177Lu-PSMA-I&T in Japan. The completion of patient dosing in the Phase 2 trial is a significant step in its development of PSMA-targeted theranostics for prostate cancer patients in Japan.
Importance 90.0 Sentiment 70.0
cnt
Japan
Japan is the primary location for the Phase 2 clinical trial of 64Cu-PSMA-I&T, with future regulatory submission and commercialization efforts focused on this market. The event addresses the prevalence of prostate cancer in Japan.
Importance 80.0 Sentiment 50.0
per
Renaud Dehareng
Renaud Dehareng, CEO of Curium Pharma, commented on the significance of the trials in expanding access to radiopharmaceuticals in Asia, highlighting the partnership's role in delivering transformative solutions.
Importance 50.0 Sentiment 60.0
per
Patrick C. Reid
Patrick C. Reid, President & CEO of PeptiDream, emphasized the importance of the patient dosing completion as a milestone for PeptiDream's radiopharmaceutical pipeline and theranostics strategy.
Importance 50.0 Sentiment 60.0
per
Masato Murakami
Masato Murakami, President of PDRadiopharma and Executive Vice President of PeptiDream, expressed satisfaction with the completion of patient dosing, acknowledging the strong collaboration and its importance for prostate cancer patients in Japan.
Importance 40.0 Sentiment 60.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.